D&P Bioinnovations company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Incubator/Accelerator | Alive

About D&P Bioinnovations

D&P Bioinnovations is a regenerative medicine company developing an implantable, bioresorbable medical device to regenerate a damaged esophagus within the body.

D&P Bioinnovations Headquarter Location

10246 Wateridge Circle Unit 204

San Diego, California, 92121,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing D&P Bioinnovations

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

D&P Bioinnovations is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Medical Devices

8,378 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest D&P Bioinnovations News

Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in Humans

Nov 16, 2021

November 16, 2021 01:00 AM Eastern Standard Time TOKYO & MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )--SanBio Company Limited (hereafter, “the Company”) hereby announces that it entered into a business partnership agreement with D&P Bioinnovations, Inc. (San Diego, California; hereafter, “D&P”), a US-based regenerative medicine company, regarding the development and commercialization of a medical device implant utilizing the Company’s regenerative medicine MSC2 for the regeneration of esophageal tissue in humans on November 15, 2021. 1. Overview of the business partnership Under the partnership agreement, SanBio will grant D&P a non-exclusive, non-transferable license to use MSC2 for the development and commercialization of the latter’s regenerative esophageal implant. In return, the Company will receive rights to commercialize D&P’s regenerative esophageal implant in Japan, as well as first negotiation rights to commercialize the implant in other parts of Asia. Further, the Company will receive tiered royalties (up to 2.5%) for D&P’s sales of the implant outside Japan. In case D&P out-licenses its regenerative esophageal implant to a third party, the Company will be entitled to a certain proportion (up to 20%) of the profits D&P earns from out-licensing the implant. In terms of major expenses, SanBio will cover expenses required for the development of manufacturing processes of MSC2 while D&P will shoulder expenses for the development of the regenerative esophageal implant in all countries except Japan. Keita Mori, CEO of SanBio, commented as follows on the partnership agreement: D&P has extensive knowledge and highly specialized expertise in the field of regenerative esophageal implants. We believe our collaboration with D&P, which includes the supply of MSC2, will lead to development of a medical device implant that can provide substantial potential benefits to patients suffering from esophageal damages. Dr. Derek Dashti, CEO of D&P, commented as follows: We at D&P Bioinnovations are pleased to cooperate with SanBio, a leader in regenerative medicine research development, in our development of regenerative esophageal implants. D&P is a regenerative medicine company focused on repairing damaged tissue/organs with engineered biomaterials and stem cells. We look forward to collaborating with SanBio on the development of our off-the-shelf engineered platform organ regenerative implant for our first application to treat and regenerate a severely damaged esophagus due to cancer, illness, and/or physical trauma. This collaboration is exciting to continue our work in changing and translating the paradigm of regenerative medicine therapeutics through the use of D&P’s novel engineered off-the-shelf tissue/organ regenerative implants. 2. Overview of business partner (1)

  • Where is D&P Bioinnovations's headquarters?

    D&P Bioinnovations's headquarters is located at 10246 Wateridge Circle, San Diego.

  • What is D&P Bioinnovations's latest funding round?

    D&P Bioinnovations's latest funding round is Incubator/Accelerator.

  • Who are the investors of D&P Bioinnovations?

    Investors of D&P Bioinnovations include MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.